136 related articles for article (PubMed ID: 1930937)
1. Multiple changes in apoprotein B containing lipoproteins after ethanol withdrawal in alcoholic men.
Kervinen K; Savolainen MJ; Kesäniemi YA
Ann Med; 1991 Oct; 23(4):407-13. PubMed ID: 1930937
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
3. Plasma lipoprotein changes during abstinence in chronic alcoholics.
Weidman SW; Beard JD; Sabesin SM
Atherosclerosis; 1984 Aug; 52(2):151-66. PubMed ID: 6433939
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
5. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
[TBL] [Abstract][Full Text] [Related]
8. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
9. Influence of obesity on the metabolism of apolipoprotein B in humans.
Egusa G; Beltz WF; Grundy SM; Howard BV
J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
[TBL] [Abstract][Full Text] [Related]
10. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
11. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
12. Increases in dietary cholesterol and fat raise levels of apoprotein E-containing lipoproteins in the plasma of man.
Cole TG; Patsch W; Kuisk I; Gonen B; Schonfeld G
J Clin Endocrinol Metab; 1983 Jun; 56(6):1108-15. PubMed ID: 6841553
[TBL] [Abstract][Full Text] [Related]
13. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
[TBL] [Abstract][Full Text] [Related]
14. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
Taskinen MR; Packard CJ; Shepherd J
Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
[TBL] [Abstract][Full Text] [Related]
15. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1726-32. PubMed ID: 12377756
[TBL] [Abstract][Full Text] [Related]
16. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Arad Y; Ramakrishnan R; Ginsberg HN
J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
[TBL] [Abstract][Full Text] [Related]
18. Atherogenicity of triglyceride-rich lipoproteins.
Krauss RM
Am J Cardiol; 1998 Feb; 81(4A):13B-17B. PubMed ID: 9526808
[TBL] [Abstract][Full Text] [Related]
19. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Mackness M
Arterioscler Thromb; 1992 Aug; 12(8):920-8. PubMed ID: 1637789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
